Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statins and diabetes.

Rafael Carmena1, D John Betteridge

  • 1Endocrine Service, Hospital Clínico Universitario, University of Valencia, Avda Blasco Ibañez 15, 46010 Valencia, Spain.

Seminars in Vascular Medicine
|April 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Present and future of drug therapy in hypertension: an overview.

Blood pressure·2024
Same author

Cardiovascular prevention in diabetes mellitus. Is it appropriate to speak of moderate or intermediate risk?

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2023
Same author

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2022
Same author

Arteriosclerosis and other diseases in heads of government and its consequences for the population.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2021
Same author

Chronic kidney disease as a cardiovascular risk factor.

Journal of hypertension·2020
Same author

Diabetogenic Action of Statins: Mechanisms.

Current atherosclerosis reports·2019
Same journal

Fibrin D-dimer and cardiovascular risk.

Seminars in vascular medicine·2005
Same journal

D-dimer testing in ischemic stroke and cerebral sinus and venous thrombosis.

Seminars in vascular medicine·2005
Same journal

D-dimer testing in pregnancy.

Seminars in vascular medicine·2005
Same journal

D-dimer levels, constitutional thrombophilia, and venous thrombosis prediction: clinical aspects and implications.

Seminars in vascular medicine·2005
Same journal

D-dimer, oral anticoagulation, and venous thromboembolism recurrence.

Seminars in vascular medicine·2005
Same journal

Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools.

Seminars in vascular medicine·2005
See all related articles

Diabetic dyslipidemia significantly increases cardiovascular risk. New therapies targeting insulin resistance and lipid metabolism, like PPAR-alpha/gamma agonists, show promise for managing atherogenic dyslipidemia in type 2 diabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Diabetic dyslipidemia, characterized by high triglycerides, low HDL cholesterol, and small, dense LDL, is a major contributor to cardiovascular risk.
  • These lipid abnormalities promote arterial wall lipid accumulation and atherosclerotic plaque formation.
  • Diabetes is recognized as a high-risk condition for cardiovascular disease, necessitating intensive risk-factor management.

Purpose of the Study:

  • To review the role of lipid abnormalities in cardiovascular risk for diabetic subjects.
  • To discuss current guidelines and therapeutic targets for lipid management in diabetes.
  • To explore new perspectives and potential drug development for diabetic dyslipidemia.

Main Methods:

  • Review of existing clinical guidelines (ATP III, AHA, ADA) for cardiovascular risk assessment and lipid management in diabetes.

Related Experiment Videos

  • Analysis of the pathophysiology of diabetic dyslipidemia, including insulin resistance and lipoprotein metabolism.
  • Examination of the mechanisms of action for existing and emerging lipid-lowering therapies, including fibrates and PPAR agonists.

    • Main Results:

    • Low-density lipoprotein cholesterol (LDL-C) lowering is the primary lipid-lowering target, with optimal levels below 2.6 mmol/L (100 mg/dL).
    • Statin therapy demonstrates clear benefits in reducing cardiovascular events in type 2 diabetics.
    • Emerging research suggests potential benefits from targeting high-density lipoprotein cholesterol (HDL-C) and exploring dual PPAR-alpha/gamma agonists.

    Conclusions:

    • Intensive risk-factor management, focusing on cardiovascular disease prevention, is crucial for type 2 diabetic patients.
    • Therapeutic lifestyle changes are foundational for managing hyperglycemia and metabolic syndrome.
    • Future lipid management strategies should address the underlying mechanisms of diabetic dyslipidemia, including insulin resistance and VLDL production, with novel agents like PPAR-alpha/gamma agonists.